A graphic listing President Donald Trump’s “Top 25 Achievements 2025–2026” makes this claim:
“Secured Most Favored Nation agreements to reduce the cost of many prescription drugs by price differences of 300, 400, 500, and 600 percent.”
There are two separate questions here: Did Trump actually secure Most Favored Nation drug-pricing agreements? And do the claims of 300%, 400%, 500% and 600% accurately describe the resulting price reductions?
The first part is supported by the evidence. The percentage language requires considerably more context. Assistance from Claude AI.
Trump Did Secure Most Favored Nation Drug-Pricing Agreements
The Trump administration has negotiated a series of agreements with pharmaceutical manufacturers under what it calls Most Favored Nation, or MFN, pricing.
The basic idea is that Americans should not pay substantially more for a medication than patients or governments pay in comparable developed countries.
This addresses a documented disparity in international drug prices. A Department of Health and Human Services analysis conducted with RAND found that, using 2022 data, U.S. prices across all prescription drugs were about 2.78 times prices in comparison countries. For brand-name drugs, U.S. prices were at least 3.22 times as high even after adjusting for estimated U.S. rebates. (ASPE, 2024)
Trump signed an executive order establishing his MFN policy in May 2025. The administration subsequently negotiated individual agreements with pharmaceutical manufacturers.
As of September 18, 2026, the White House reported agreements with 26 pharmaceutical manufacturers representing about 89% of the U.S. branded-drug market. The manufacturers include Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, Merck, Johnson & Johnson, AbbVie, Regeneron, Sanofi and others. The administration also announced that all 50 state Medicaid programs would participate in an MFN pricing model covering hundreds of drugs. (White House, 2026)
So the central assertion that Trump secured MFN agreements is well supported.
Some Individual Drug Discounts Are Very Large
The agreements have also resulted in substantial advertised discounts for some drugs.
When TrumpRx launched on February 5, 2026, for example, the White House reported that the monthly price of injectable Wegovy could fall from $1,349 to as low as $199, depending on dosage. Ozempic was listed as falling from $1,028 to an average of $350 and as low as $199. Other drugs received similarly large direct-purchase discounts.
But this is where the “300%, 400%, 500%, even 600%” language becomes important.
A Price Cannot Be Reduced by 600%
Consider the Wegovy example.
The old price was:
$1,349
The advertised new price was as low as:
$199
The conventional calculation for a price reduction is:
($1,349 − $199) ÷ $1,349 × 100 = 85.2%
So the price fell approximately 85%.
It did not fall 578%, 600% or anything approaching those figures. A percentage reduction cannot exceed 100%, because a 100% reduction already means the price has fallen to zero.
Where does the much larger percentage come from?
If the denominator is reversed, the calculation becomes:
($1,349 − $199) ÷ $199 × 100 = 577.9%
That means the old $1,349 price was approximately 578% higher than the new $199 price.
That is mathematically legitimate. But it describes how much higher the old price was relative to the new one. It does not mean the price was reduced by 578%.
This difference in denominators explains Trump’s repeated references to price “differences” of 300%, 400%, 500% and 600%.
Trump himself has sometimes expressed the changes in the more conventional fashion. In September 2026, while discussing the same policy, he said a simpler description was that prescription drug prices had been reduced by roughly 60%, 70%, 80% or 90%, depending on the medication.
That formulation accurately describes a percentage reduction.
Do Americans Now Always Pay the World’s Lowest Drug Prices?
No.
The MFN agreements are significant, but they do not mean that every American prescription drug is now available at the world’s lowest price.
An independent September 2026 analysis by KFF examined 32 brand-name drugs available through TrumpRx for which international comparisons could be made.
KFF found that TrumpRx was cheaper than the average price in comparable countries for 17 of the 32 drugs.
For the other 15 drugs, the TrumpRx price was higher than the comparison-country average.
Only five of the 32 drugs had TrumpRx prices lower than every other country examined. Conversely, 13 drugs had TrumpRx prices higher than every other country in the comparison. (McGough et al., 2026)
That doesn’t mean the MFN initiative has failed to reduce prices. It means claims that Americans universally receive the world’s lowest price go beyond what the available comparative data demonstrate.
The Agreements Also Don’t Work Identically for Every Patient
Another complication is that “MFN pricing” encompasses several different arrangements.
Manufacturers have agreed to provide MFN pricing in certain circumstances to Medicaid programs, introduce certain new drugs at MFN prices and make selected products available directly to consumers at discounted prices.
TrumpRx, for example, initially provided direct-purchase prices through manufacturer programs and coupons. The White House separately called on Congress to make TrumpRx purchases easier to cover through health plans.
KFF has also noted that important details of many individual manufacturer agreements have not been publicly disclosed, making it difficult for outside researchers to independently evaluate all of their provisions and long-term effects. (Cubanski, 2026)
Bottom Line
The underlying achievement in the graphic is real: the Trump administration negotiated Most Favored Nation pricing agreements with numerous major pharmaceutical manufacturers, and some medications have received very large discounts.
By September 2026, the administration reported agreements with 26 manufacturers covering roughly 89% of the branded-drug market. Some individual TrumpRx prices have been reduced by 50%, 70%, 80% or more.
But the 300%–600% figures should not be interpreted as percentage price reductions.
When a drug falls from $1,349 to $199, for example, the actual reduction is about 85%. The old price was about 578% higher than the new price, which is a different calculation.
And independent evidence does not support a blanket conclusion that every drug subject to Trump’s initiatives is now cheaper in the United States than everywhere else. In KFF’s September 2026 comparison, TrumpRx prices were below the international average for roughly half of the drugs studied and above it for roughly half.
A more precise description of the achievement would therefore be:
The Trump administration secured MFN agreements with major drug manufacturers that have substantially reduced the prices of some prescription drugs, in certain cases by 50% to 90%. References to 300%–600% describe the old price relative to the new price, not the percentage by which the price was reduced.
References
Assistant Secretary for Planning and Evaluation. (2024, January 31). Comparing prescription drugs in the U.S. and other countries: Prices and availability. U.S. Department of Health and Human Services.
Cubanski, J. (2026, January 15). President Trump proposes codifying MFN drug pricing deals but key details are missing. KFF.
McGough, M., Cotter, L., Telesford, I., Lo, J., Ferguson, A., Gupta, A., & Cubanski, J. (2026, September 24). How TrumpRx brand-name drug prices compare to other countries. KFF/Peterson-KFF Health System Tracker.
The White House. (2026, February 5). Fact sheet: President Donald J. Trump launches TrumpRx.gov to bring lower drug prices to American patients.
The White House. (2026, September 18). Fact sheet: President Donald J. Trump announces lower drug prices for all 50 state Medicaid programs.